Basilea Pharmaceutica (BSLN) Stock Statistics & Valuation Metrics

Basilea Pharmaceutica has a market cap or net worth of CHF793.76M. The enterprise value is CHF644.92.

Basilea Pharmaceutica has 13,425,260 shares outstanding. The number of shares has decreased by -2.65% in one year.

Basilea Pharmaceutica’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 19.12%.

The current PE Ratio of Basilea Pharmaceutica is 15.2. Basilea Pharmaceutica’s PEG ratio is -0.34.

In the last 12 months, Basilea Pharmaceutica had revenue of 232.40M and earned 40.20M in profits. Earnings per share was 3.29.

In the last 12 months, operating cash flow was 58.01M and capital expenditures -2.71M, giving a free cash flow of 55.30M billion.

Basilea Pharmaceutica pays an annual dividend of CHF5, resulting in a dividend yield of ―

Basilea Pharmaceutica upcoming earnings date is Feb 16, 2027, TBA (Confirmed).

Basilea Pharmaceutica as a current ratio of 5.11, with Debt / Equity ratio of 51.40%

In the past 12 months, Basilea Pharmaceutica has paid 5.60M in taxes.

Basilea Pharmaceutica EV to EBITDA ratio is 13.17, with an EV/FCF ratio of 12.29.

Basilea Pharmaceutica has CHF175.98M in cash and marketable securities with CHF83.44M in debt, giving a net cash position of CHF92.54M billion.

Gross margin is 87.67%, with operating margin of 22.20%, and net profit margin of 17.30%.

The average price target for Basilea Pharmaceutica is ―, which is 11.43% higher than the current price. The consensus rating is ―